RxDoctor Payments Data

Peggy Derusso

Primary Care · Philadelphia, PANPI 1144860735

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 35.4% of the total.

$2,614in general payments, 2019–2025

Across 154 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$925
  • Astellas Pharma US Inc$312
  • Boehringer Ingelheim$201
  • GSK$175
  • Lilly USA, LLC$151
  • Bayer$132
  • plus $720 from 22 others

What the payments were for

  • Food & beverage$2,49095%
  • Education$1245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,614 in reported general payments places this provider in the 85th percentile of 300 primary care providers in Pennsylvania.

See all primary care providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide22$23,031
TrulicityDulaglutide16$17,433
EliquisApixaban17$9,657
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp12$4,145
Valsartan32$1,048
Albuterol Sulfate HfaAlbuterol Sulfate26$1,006
Rosuvastatin Calcium47$841
Nifedipine ErNifedipine17$802
Labetalol Hcl31$743
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine25$600
Perphenazine12$588
Metoprolol Succinate30$563
Atorvastatin Calcium39$525
Enalapril Maleate14$500
Clonazepam21$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$151$40,46438 claims
PfizerEliquis$47$9,65717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 300 primary care providers in Pennsylvania.

Other primary care in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →